As part of scientific exchange, Novartis is providing the most recent abstract(s) and/or presentation(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Before prescribing any product, always refer to the Prescribing Information (PI), Summary of Product Characteristics (SmPC), or product information as appropriate in your country. Information is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access.
This is for your background and educational purposes only and may not be altered or further disseminated in any fashion.
For distribution in response to an unsolicited request for medical information subject to local approval.
Content to be used in accordance with local CPO guidelines
Efficacy and Safety of Dabrafenib plus Trametinib in Patients with Radioactive Iodine-Refractory BRAF V600-mutant Differentiated Thyroid Cancer
Ming Gao, Young J. Park, Chia-Chi Lin, Monika K. Krzyzanowska, Zhiyong Li, Hui-Jen Tsai, Feng Shi, Jianwu Qin, Swee H. Choong, Yansong Lin, Yuan Zhang, Jin H. Kang, Ana O. Hoff, Monique Tan, Michael Roughton, Michaela Paul, Lori J. Wirth
Proferred Paper/Oral Presentation #2987O
Karlsruhe Auditorium - Hall 5.2 | Saturday, October 18, 2025 | 10:35-10:45 CEST (Proffered Paper/Oral Presentation) | 10:55-11:05 CEST (Discussion)